CanariaBio

Focus: CanariaBio is a Seoul-based biotechnology company focused on oncology, specifically cancer immunotherapies targeting ovarian and related cancers. The company operates as a pre-revenue biotech with a concentrated pipeline around a single lead asset.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CanariaBio

AI assessmentNot Hiring

No open roles listed right now. Follow CanariaBio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Oregovomab

Cancer of Ovary

Phase 1

Clinical Trials (1)

NCT03162562The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

Phase 1

Help build intelligence for CanariaBio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused oncology pipeline with Oregovomab advancing through multiple Phase 2 and Phase 3 indications, offering deep disease expertise
Based in Seoul with access to Korean biotech ecosystem and potential regulatory tailwinds in Asian markets
Early-stage company structure allows hands-on impact on drug development strategy and clinical decision-making

Watch Out For

Pre-revenue status with no disclosed funding or financial data creates uncertainty about runway and long-term viability
Zero active job openings and no disclosed employee count suggest minimal hiring and possible resource constraints
Limited publication record (0 publications) and sparse public visibility raise questions about scientific credibility and market traction

Generated by Claude from CanariaBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Oregovomab

Epithelial Ovarian Cancer

Phase 1/2

Oregovomab

Ovarian Cancer by FIGO Stage

Phase 1/2

Clinical Trials (1)

NCT04938583Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2

Oregovomab

Recurrent Ovarian Cancer

Phase 2

Clinical Trials (1)

NCT05335993A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Phase 2

Orevogomab+PLD

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Phase 2

Clinical Trials (1)

NCT05407584Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Phase 2

Oregovomab

Ovarian Neoplasm Epithelial

Phase 2

Clinical Trials (1)

NCT05605535Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

5 pipeline

Marketed

Pipeline